Evidence map›Paper›PMID 29516267›Full record

ReviewCurrent HIV/AIDS reports2018

The Influence of Cervicovaginal Microbiota on Mucosal Immunity and Prophylaxis in the Battle against HIV.

Mara Farcasanu, Douglas S Kwon

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current HIV/AIDS reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Microbiome Studies in Non-human Primates.Current HIV/AIDS reports · 2021
    Review
  7. Article
  8. Review
  9. Review
  10. Assessment ofmSphere · 2020
    Article
  11. Observational
  12. Microbiota in viral infection and disease in humans and farm animals.Progress in molecular biology and translational science · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mara FarcasanuRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, 400 Technology Square, Cambridge, MA, 02139, USA.
Douglas S KwonRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, 400 Technology Square, Cambridge, MA, 02139, USA. dkwon@mgh.harvard.edu.

Funding

The enteric microbiome in treated and progressive HIV infectionR01DK101354 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI KWON, DOUGLAS, VIRGIN, HERBERT W · 2014 to 2018
$3.7M
Inflammation and the vaginal metagenome in HIV acquisitionR01AI111918 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KWON, DOUGLAS, VIRGIN, HERBERT W · 2014 to 2017
$2.5M
NIAID NIH HHS R01 AI111918NIDDK NIH HHS R01 DK101354
6 · The paper itself

Abstract

purpose of reviewYoung women in sub-Saharan Africa bear a disproportionate burden of the global HIV epidemic. In this review, we examine how cervicovaginal microbiota modulate structural and immune defenses in the female genital tract and influence HIV susceptibility. RECENT

findingsHighly diverse, anaerobic cervicovaginal microbiota prevalent in sub-Saharan African women increase HIV acquisition risk by over fourfold. These bacteria weaken the barrier properties of the vaginal mucosa and increase local inflammation and HIV target cell recruitment, creating an environment permissive to HIV. These communities also diminish the prophylactic efficacy of topical tenofovir and therefore may modulate both biological susceptibility to HIV and the effectiveness of pre-exposure prophylaxis (PrEP). Cervicovaginal bacteria influence multiple reproductive health outcomes, including HIV acquisition. High-diversity, low Lactobacillus abundance cervicovaginal communities prevalent in many regions with high HIV incidence are associated with increased HIV susceptibility. A better understanding of the host-microbial interactions mediating this risk is important to reduce HIV infections, particularly among women living in sub-Saharan Africa.

Indexed as

Africa South of the SaharaAnti-HIV AgentsCervix UteriFemaleHIVHIV InfectionsHumansImmunity, MucosalLactobacillusMicrobiotaPre-Exposure ProphylaxisTenofovirVaginaAnti-HIV AgentsTenofovirCervicovaginal microbiomeGenital inflammationHIV/AIDSPre-exposure prophylaxis (PrEP)

Identifiers

PMID29516267

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.